Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10920MR)

This product GTTS-WQ10920MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10920MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4747MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ12715MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ5917MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ12756MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ7592MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ11334MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ11308MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ6657MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW